A

Akari Therapeutics plc
D

AKTX

1.16000
USD
-0.02
(-1.69%)
Market Closed
Volume
0
EPS
-0
Div Yield
-
P/E
-0
Market Cap
37,324,589
OverviewSignalsIdeasNews
Related Instruments
A
ACIU
0.07000
(3.50%)
2.07000 USD
A
AXGN
-0.180
(-1.63%)
10.895 USD
B
BHC
-0.14000
(-1.97%)
6.98000 USD
BMY
BMY
-0.525
(-1.10%)
47.080 USD
C
CETX
0.01000
(0.82%)
1.23000 USD
C
COCP
-0.01000
(-0.67%)
1.49000 USD
C
CPRX
0.020
(0.09%)
21.460 USD
C
CTRM
0.03000
(1.35%)
2.25000 USD
C
CTXR
0.09000
(4.27%)
2.20000 USD
D
DARE
0.02000
(0.84%)
2.40000 USD
E
EVOK
-0.16000
(-6.02%)
2.50000 USD
I
ICAD
0.03500
(0.94%)
3.77000 USD
I
INMD
0.005
(0.03%)
15.210 USD
K
KTOS
1.380
(3.19%)
44.660 USD
L
LXRX
0.00020
(0.02%)
0.91110 USD
O
OPRX
0.326
(2.49%)
13.430 USD
O
OVID
0.00830
(2.51%)
0.33880 USD
P
PAAS
0.230
(0.80%)
29.020 USD
P
PLAG
-0.06000
(-6.98%)
0.80000 USD
R
REKR
0.03000
(2.50%)
1.23000 USD
R
RGEN
0.490
(0.39%)
127.440 USD
S
SCYX
0.02160
(2.99%)
0.74490 USD
S
SHIP
0.01000
(0.15%)
6.48000 USD
S
SINT
0.06000
(1.80%)
3.39000 USD
S
SSKN
-0.08000
(-3.27%)
2.37000 USD
T
TLRY
0.03700
(7.54%)
0.52800 USD
T
TNXP
0.140
(0.40%)
35.290 USD
T
TTNP
0.07000
(1.65%)
4.32000 USD
U
USIO
0.01000
(0.61%)
1.64000 USD
More
News
Treasury Yields Decline as Market Anticipates Fed Rate Cuts

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

10 months ago
Economy News
Novo Nordisk Surges in Profit and Sales

Novo Nordisk Surges in Profit and Sales

1 year ago
Stocks News
More

Title: Akari Therapeutics plc

Sector: Healthcare
Industry: Biotechnology
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest TradersUser Reviews for Brokers
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.